Advertisement
Screener

ARS Pharmaceuticals, Inc. (SPRY) Gain (Loss) on Investments

ARS Pharmaceuticals, Inc. Gain (Loss) on Investments

ARS Pharmaceuticals, Inc. (SPRY) reported Gain (Loss) on Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.

Discontinued › Income Statement › Other Income

us-gaap:GainLossOnInvestments · last filed 2024-03-21

  • ARS Pharmaceuticals, Inc. gain (loss) on investments for fiscal 2023 was $0.00.
  • ARS Pharmaceuticals, Inc. gain (loss) on investments for fiscal 2022 was -$140.00K.
  • ARS Pharmaceuticals, Inc. gain (loss) on investments for fiscal 2021 was $0.00.
Period endGain (Loss) on Investments 12 month
2023-12-31$0.00
10-K · filed 2024-03-21
2022-12-31-$140.00K
10-K · filed 2024-03-21
2021-12-31$0.00
10-K · filed 2023-03-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85